The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The test, which was previously approved for CLL prognosis, is now cleared for use in identifying patients who may benefit from AbbVie and Genentech's Venclexta.
Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company notified the Securities and Exchange Commission of the subpoena and noted that it will delay filing its annual earnings for 2015.
Abbott's move came as somewhat of a surprise, but analysts have noted the potential for a trend in point-of-care diagnostics acquisitions.
Alere will become an Abbott subsidiary, and Alere shareholders will receive $56 per common share in cash at the completion of the transaction.
The company reported $1.22 billion in Q4 Worldwide Diagnostics sales, including $126 million in molecular diagnostics sales due to growth in infectious disease testing.
Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.